LB Pharmaceuticals (LBRX) vs MannKind (MNKD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
LB Pharmaceuticals (LBRX) has outperformed MannKind (MNKD) over the past year, gaining 138.0% versus a loss of 36.0%. LB Pharmaceuticals is the larger company by market cap ($1.20 billion vs $1.06 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LBRX | MNKD |
|---|---|---|
| Share price | $37.22 | $3.29 |
| Market cap | $1.20B | $1.06B |
| 1-day change | +7.54% | -3.80% |
| YTD return | +67.21% | -41.98% |
| 1-year return | +137.98% | -35.99% |
| 5-year return | — | -35.36% |
| P/E ratio (TTM) | 372.20 | — |
| Forward P/E | — | 25.80 |
| EPS (TTM) | $0.10 | $-0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $50.16 | $6.51 |
| 52-week low | $14.32 | $2.23 |
| Distance from 52-week high | -25.80% | -49.46% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +53.95% | +138.30% |
| Average volume | 344.34K | 4.51M |
| Shares outstanding | 32.26M | 321.54M |
| Employees | 49 | 591 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LBRX has outperformed MNKD by 174.0 percentage points over the past year.
About LB Pharmaceuticals
LBRX stock →LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
About MannKind
MNKD stock →MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 591 employees
LBRX vs MNKD FAQ
Which is bigger, LB Pharmaceuticals or MannKind?
LB Pharmaceuticals (LBRX) is larger, with a market capitalization of $1.20B compared with $1.06B for MannKind (MNKD).
Which stock has performed better over the past year, LBRX or MNKD?
LBRX returned +137.98% over the past 12 months, compared with -35.99% for MNKD (price return, excluding dividends). Past performance does not predict future results.
Are LB Pharmaceuticals and MannKind in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.